Abstract: A process for the working up of a product stream from the epoxidation of olefins that contains olefin, olefin oxide, water-miscible organic solvent and water, by separating this product stream into an overhead product containing olefin, olefin oxide and organic solvent, and into a bottom product containing organic solvent and water, wherein the separation takes place in a pre-evaporator with less than 10 theoretical separation stages at a pressure of 1.5 to less than 3 bar, and 20 to 60% of the total amount of organic solvent introduced with the product stream is removed with the overhead product and the balance remains in the bottom product. A process for the epoxidation of olefins that includes this working up stage is also disclosed.

Abstract: This invention relates to a method for preparing taxane derivatives of general formula (I) by esterification at a temperature between −10 and 60° C. of a derivative of baccatine III or 10-deacetyl baccatine III of general formula (II) by means of an acid of general formula (III), followed by replacement of the protective groupings G1, G2 and R2 of the resulting product by hydrogen atoms. In formulae (I), (II) or (III), Ar stands for an aryl radical; R stands for hydrogen or acetyl; R1 is benzoyl or ter.butoxycarbonyl; G1 is a hydroxy function protective grouping, G2 stands for the acetyl radical or a hydroxy function protective grouping, and R2 stands for a hydroxy function protective grouping.

Abstract: Taxanes having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.

Abstract: The present invention relates to benzopyrans and benzoxepines of formula (I), wherein X, A, R1, R2 and (R)p have the meanings as given in claim 1, which can be used in the treatment of dislipidaemias, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to processes allowing the preparation of these compounds.

Abstract: A cytotoxic agent comprising one or more polyethylene glycol-containing taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more polyethylene glycol-containing taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more polyethylene glycol-containing taxanes linked to a cell binding agent.

Abstract: Disclosed is a method of recovering and purifying 3,4-epoxy-1-butene (epoxybutene) from an epoxidation effluent gas obtained by the vapor phase, catalytic, partial oxidation of 1,3-butadiene (butadiene) with molecular oxygen in the presence of a silver catalyst wherein the epoxybutene-laden epoxidation product gas is reacted with a water-miscible solvent to absorb the epoxybutene. The disclosed process includes a method of separating epoxybutene from the solvent and other reaction by-products by a novel combination of distillation and decantation steps.

Abstract: Methods of preparing methylthiomethyloxy taxoids of formula (XXXIV) from baccatin and &bgr;-lactam are presented. These new taxoids display noteworthy anti-tumor and anti-leukemic properties.

Abstract: Continuous process for manufacturing an oxirane, according to which an olefin is reacted at a temperature above 35° C. and for a period of more than 48 hours, with a peroxide compound in the presence of a zeolite-based catalyst and in the presence of a metal salt, in which the catalyst undergoes no regeneration treatment and in which the rate of deactivation of the catalyst, expressed as being a percentage of the conversion of the peroxide compound lost per gram of oxirane produced per gram of zeolite determined after establishing the reaction conditions, i.e. after the consumption of 2.5 mol of peroxide function per gram of zeolite, is less than or equal to 0.15%.

Abstract: The invention relates to improved methods of producing aryl dioxoalkanoic acid compounds and derivatives useful as intermediates for diarylpyrrole therapeutic agents by the alcoholysis of benzoylcyclohexanone ketal compounds.

Abstract: Seco-baccatin III derivatives of formula: wherein R, R1-R4, R1, R11, and R111 are disclosed herein; pharmaceutical compositions comprising seco-baccatin III derivative; and methods for treating cancer, arthritis, and inhibiting angiogenesis in an animal comprising administering to a patient in need thereof a therapeutically effective amount of a seco-baccatin III derivative are disclosed.

Abstract: A process for the preparation of diglycidylether of alkoxylated resorcinol using novel catalysts is disclosed. In particular, it has been found that antimony, indium and tellurium halides are effective catalysts for preparation of the diglycidylether of alkoxylated resorcinol.

Abstract: A process for the production of an oxirane compound by reaction of an olefin with a hydroperoxide reactant in the presence of a solid epoxidation catalyst, wherein the olefin and hydroperoxide reactants are first reacted in it least two fixed bed reactors packed with fresh catalyst, olefin being fed serially to said reactors and hydroperoxide reactant being fed in parallel to said reactors and thereafter the reactor effluent from the last of said reactors is passed to as least one further fixed bed reactor packed with epoxidation catalyst which has been at least partially deactivated.

Abstract: The present invention relates to a semi-synthetic process to convert a naturally occurring taxane into a suitable starting material for the synthesis of paclitaxel and related compounds. Specifically, the present invention relates to a process for the conversion of 9-dihydro-13-acetylbaccatin III into a 7-protected baccatin III which can then be used as starting material for the synthesis of taxane derivatives such as paclitaxel, docetaxel, cephalomannine and other taxanes structurally related to baccatin III. The method as described uses a preparative scale technique which is amenable to commercial scale-up.

Abstract: A no-flow reworkable epoxy underfill is provided for use in an electronic packaged system which incorporates an integrated circuit, an organic printed wire board, and at least one eutectic solder joint formed therebetween. An exemplary embodiment of the encapsulant includes: a cycloaliphatic epoxide; an organic hardener; a curing accelerator; and a fluxing agent wherein said cycloaliphatic epoxide includes a carbonate or carbamate group. The encapsulant can also include a filler, such as a silica filler. A method is also provided for forming the aforementioned reworkable epoxy underfills.

Abstract: Novel compounds that are anti-angiogenic or immunosuppressive are described. Also described are methods for determining if an animal is at risk for a disease involving abnormal angiogenesis or an immune reaction resulting in pathology comprising evaluating an aspect of MetAP2 metabolism or structure; methods for identifying agents that are anti-angiogenic or immunosuppressive comprising evaluating the effect of the agent on an aspect of MetAP2 metabolism; methods for treating a cell having an abnormality in metabolism or structure of MetAP2; and methods for treating abnormal angiogenesis or an immune reaction which results in pathology in an animal. Pharmaceutical compositions are also provided.

Abstract: Salicylamide derivatives represented by formulae (1a) and (1b); intermediates in the production thereof; a process for producing the same; and drugs containing the same as the active ingredient. The salicylamide derivatives represented by formulae (1a) and (1b) are useful as anti-inflammatory agents and immunosuppressive agents which exert an effect of inhibiting the activation of NF-&kgr;B with little side effects.

Abstract: A process for the preparation of an oxirane, aziridine or cyclopropane of formula (I), wherein X is oxygen, NR4 or CHR5; R1 is hydrogen, alkyl, aryl, heteroaromatic, heterocyclic or cycloalkyl; R2 is hydrogen, alkyl, aryl, heteroaromatic, CO2R8, CHR14NHR13, heterocyclic or cycloalkyl; or R1 and R2 join together to form a cycloalkyl ring; R3 and R10 are, independently, hydrogen, alkyl, aryl, heteroaromatic, CO2R8, R83Sn, CONR8R9, trialkylsilyl or triarylsilyl; R4 is an electron withdrawing group; R5 is alkyl, cycloalkyl, aryl, heteroaromatic, SO2R8, SO3R8, COR8, CO2R8, CONR8R9, PO(R8)2, PO(OR8)2 or CN; R8 and R9 are independently alkyl or aryl; and R13 and R14 are independently hydrogen, alkyl or aryl is provided. The process comprises degrading a compound of formula (II), (IIa), (IIb) or (IIc): wherein R3 and R10 are as defined above; Y is a cation; depending on the nature of Y, r is 1 or 2; and L is a suitable leaving group, to form a diazo compound.

Abstract: The present invention features methods and compounds for treating or preventing a cell death disease or inflammation, and methods for synthesizing wedelolactone.

Abstract: Taxane derivatives having alternative C10 substituents.

Abstract: The present invention relates to a novel process for producing a &dgr;-lactone of the formula: using an acyl halide of the formula: wherein R1, R2 R3 and X are described herein, as well as novel intermediates. In particular, the present invention relates to a process for enantioselectively producing the (R)-&dgr;-lactone.